Drug patent cliffs are no longer a guessing game. AI is turning them into a forecast.
For years, life sciences teams have treated patent expiration and litigation risk like weather: you can track signals, but you cant truly predict the stormuntil it hi…

Patent thickets arent just a legal inconveniencetheyre a business model. When a brands portfolio sprawls across overlapping Orange Book listings, method-of-use claims, formulation patents, and evergreen continuations, the generic path can feel less lik…

Blockbuster drugs dont just have patentsthey have formulas. And if youre trying to compete in the generics, biosimilars, or design-around space, the real battleground often isnt the active ingredient. Its the formulation.
Thats the core idea behind for…

Patent risk isnt an R&D problem. Its a board problem.
In pharma, IP litigation often shows up on the org chart as a legal matteruntil it doesnt.
A generic challenge, an adverse claim construction, a delayed settlement, a failed appeal: these events…

Designing Around Formulation Patents: The Generic Developers Playbook Is Getting Sharper
In generic drug development, the hardest part isnt always the scienceits the chessboard.
Formulation patentsthose covering how a drug is made, structured, stabiliz…

Pharma forensics is having a momentand its not because the science got easier.
Its because the battlefield has moved. In the race to protect revenue, companies arent only defending active ingredients anymore. Theyre defending how drugs are made, formul…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In pharma, generic doesnt mean simple. It means strategic. And nowhere is that more true than in the quiet battleground of secondary formulation patentsthe pat…

Patent cliff or patent opportunity? Mapping blockbuster expirations for strategic supply-chain readiness
The market loves a cliff. But supply chains dont.
When blockbuster drug patents approach expiration, the conversation usually turns to pricing pres…

Most patent searches miss the real story. Heres whyand how AI is changing the game.
If youve ever run a prior-art search, you know the uncomfortable truth: the right reference often isnt the one that matches your keywords. Its the one that matches the …

Most design-around strategies fail for one reason: they start with ideasnot claims.
In pharma IP, the difference between a clever workaround and a costly litigation risk often comes down to a single question: what exactly does the competitors patent cl…